<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003620/" ref="ordinalpos=2882&amp;ncbi_uid=2639264&amp;link_uid=PMC3003620" image-link="/pmc/articles/PMC3003620/figure/F1/" class="imagepopup">Figure 1.  From: Targeted therapy in lymphoma. </a></div><br /><div class="p4l_captionBody"><b>The PI3K/Akt signaling pathway</b>. Reprinted with permission from Altman JK, Platanias LC: Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol. 2008, <b>15</b>:88-94.</div></div>